Go to main content
Tricals - The highway towards a cure
CRESLA: Centro Regionale Esperto SLA di Torino

University of Turin

Italy - Torino

The Torino ALS Centre (CRESLA) performs basic and clinical research, while at the same time providing care for ALS patients.

The Turin ALS centre represents the Regional ALS Reference Centre for Piemonte Region and currently has more than 350 ALS patients followed up. The centre is involved in clinical research (phase I,II and III clinical trials, genetics, deep phenotyping) and basic research in collaboration with several laboratories in Italy and Europe. The Turin ALS Centre (CRESLA Torino) is part of the “Rita Levi Montalcini” Department of Neuroscience of the University of Turin (UNITO) and of the Medical Department of Neuroscience and Mental Health of the Città della Salute e della Scienza di Torino (City of Health and Science of Turin), Neurology 1 Unit. We are constantly involved in international randomized clinical trials on innovative drugs in ALS. We have a multidisciplinary group and a daily ALS clinic providing genetic counseling, psychological, neuropsychological andneurophysiological services.

Specialists in this centre

Adriano Chiò

Professor of Neurology

Andrea Calvo

Associate Professor of Neurology

Cristina Moglia

Associate Professor of Neurology

Antonio Canosa

Assistant Professor of Neurology

Umberto Manera

Assistant Professor of Neurology

Current trials in this centre

Open for participation

ATLAS

Phase 3
Industry
SOD1

This trial evaluates the efficacy and safety and of an investigational drug for pre-symptomatic carriers of the SOD1 gene.

More about this trial

Closed for participation

FUSION

Phase 3
Industry
FUS

This study investigates the safety & efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene.

More about this trial

Archived

TUDCA-ALS

Phase 3
IIT
No

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

More about this trial

Archived

PHOENIX

Phase 3
Industry
No

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035'.

More about this trial

Archived

CardinALS

Phase 2
Industry
No

The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms.

More about this trial

Archived

ADORE

Phase 3
Industry
No

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of FNP122 for people with ALS.

More about this trial

Archived

VALOR

Phase 3
Industry
SOD1

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with ALS.

More about this trial

Archived

APL2-ALS-206 trial

Phase 2
Industry
No

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS.

More about this trial

Archived

ALXN1210-ALS-308 trial

Phase 3
Industry
No

This study is designed to test the efficacy and safety of intravenous Ravulizumab in patients with ALS.

More about this trial

Contact this centre

If you would like to contact us or register for a trial, leave your details here.